MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
MeiraGTx has secured a multi-million dollar financing deal with Oberland Capital to advance the commercialization of two gene therapy candidates.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
MeiraGTx Holdings has reached a financing agreement involving royalty financing and an equity addition. The capital infusion is intended to support the company's efforts to bring two gene therapies toward commercialization.
Additionally, the company is using the funds to retire existing debt held by Perceptive. Seeking Alpha and Investing.com note that the deal is being viewed as a catalyst for the company's BLA filing, which is anticipated for the first half of 2027, and has maintained analyst ratings.
Future developments to watch include the progression of the BLA filing timeline and further data readouts for AAV2-hAQP1. Investors are also monitoring the impact of the Bota-Vec acquisition as the company transitions toward the commercialization phase.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (86% supported) Updated just now.
Quick answers
What is the primary purpose of the new funding?
The capital is directed toward the commercialization of two gene therapies and the retirement of existing debt.
When does MeiraGTx expect to file for a BLA?
Coverage indicates that a BLA filing is expected during the first half of 2027.
Who provided the financing?
The financing was secured through Oberland Capital.
Coverage (5)
- MeiraGTx Secures Up To $375 Million Royalty Financing, Adds $10 Million Equity, Retires Perceptive Debt TradingView · 22h ago
- Exclusive BAC Article: MeiraGTx; AAV2-hAQP1 Q2 207 Data Xerostomia, BLA Filing 1st Half 2027, Bota-Vec Acquisition, Oberland Capital Cash Infusion, And Catalysts (NASDAQ:MGTX) Seeking Alpha · 22h ago
- MeiraGTx Holdings (MGTX) Is Up 8.5% After Securing US$425M In New Funding Pathways simplywall.st · 22h ago
- H.C. Wainwright reiterates MeiraGTx stock rating on financing deal Investing.com · 22h ago
- MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization Fierce Biotech · 22h ago
Topics
Related trends
Brain tumors: New vaccine offers patients hope for more time
Clinical trials for a personalized neoantigen dendritic cell vaccine for glioblastoma are underway, with reported data on survival gains.
FDA approves Vera Therapeutics kidney disease treatment
Vera Therapeutics stock gains momentum following the FDA’s accelerated approval of its new kidney disease drug, Trutakna.
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Vertex Pharmaceuticals has announced a $10 billion acquisition of Crinetics, signaling a significant shift in the biopharma landscape.
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex Pharmaceuticals is expanding into the endocrinology sector through a $10 billion acquisition of Crinetics Pharmaceuticals.
Scientists discover why exercise reverses muscle aging
New research links exercise to gene-level muscle rejuvenation—and a surprising cancer connection
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis has announced a deal to acquire U.K.-based cancer biotech Myricx Bio in a transaction valued at up to $1.5 billion.